B7-33

Description

Strength: 5mg
CAS: 1818415-56-3
Chemical Formula: C₁₃₁H₂₂₉N₄₁O₃₆S
Molecular weight: 2986.54 g/mol
Peptide Sequence: Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu-NH₂
Storage: Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
Shelf life: 24 months from the manufacturing date.

B7-33 is a synthetic, single-chain peptide derived from the B-chain of the human hormone relaxin-2. It has been studied as a selective relaxin-based peptide analog, designed to retain certain biological activities associated with relaxin while minimizing others. Research has primarily focused on tissue remodeling, extracellular matrix regulation, and fibrotic processes.

B7-33 is manufactured for controlled laboratory research environments and is not intended for clinical use.

• Purity: High research-grade purity (≥95% typical for analytical-grade peptides)
• Sequence: Val-Ile-Lys-Leu-Ser-Gly-Arg-Glu-Leu-Val-Arg-Ala-Gln-Ile-Ala-Ile-Ser-Gly-Met-Ser-Thr-Trp-Ser-Lys-Arg-Ser-Leu-NH₂
• Molecular formula: C₁₃₁H₂₂₉N₄₁O₃₆S
• Molecular weight: 2986.54 g/mol
• CAS number: 1818415-56-3
• Storage: 2–8 °C (≤–20 °C for long-term storage)
• For laboratory research use only

B7-33 is being researched as a simplified analog of the endogenous hormone relaxin-2, which, acting at the RXFP1 receptor, is known to influence connective tissue dynamics and extracellular matrix turnover. In experimental systems, B7-33 has been reported to preferentially activate pERK1/2 signaling over cAMP pathways at RXFP1, a signaling bias that distinguishes it from native relaxin-2 in research settings. This selective signaling profile has made it a research tool in studies focused on:

• Collagen regulation
• Extracellular matrix remodeling
• Cardiac and renal tissue research models
• Fibrotic pathway investigation

Research remains preclinical and investigational in nature.

Published preclinical studies have evaluated B7-33 in controlled laboratory models, typically using:

• Microgram to milligram per kilogram dosing ranges in animal studies
• Short- to mid-duration experimental protocols depending on study design
• Parenteral administration routes in research settings

Observed outcomes in research contexts have included modulation of collagen deposition and changes in markers associated with tissue remodeling. These findings are experimental and limited to laboratory and animal research models. No clinical dosing recommendations have been established.

• Store at 2–8 °C for routine handling
• For long-term storage, keep at ≤–20 °C
• Protect from repeated freeze–thaw cycles
• Reconstitute using sterile laboratory-grade solvent under aseptic conditions
• Handle using appropriate laboratory safety procedures, including gloves and protective equipment
• Dispose of materials according to institutional biosafety guidelines

References

1. Hossain MA, Kocan M, Yao ST, et al. A single-chain derivative of the relaxin hormone is a functionally selective agonist of the G protein-coupled receptor, RXFP1. Chem Sci. 2016;7(6):3805-3819. doi:10.1039/c5sc04754d
2. Devarakonda T, Mauro AG, Guzman G, et al. B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice. J Am Heart Assoc. 2020;9(8):e015748. doi:10.1161/JAHA.119.015748
3. Samuel CS, Royce SG, Hewitson TD, Denton KM, Cooney TE, Bennett RG. Anti-fibrotic actions of relaxin. Br J Pharmacol. 2017;174(10):962-976. doi:10.1111/bph.13529

Compliance Notice

This product is intended for laboratory research use only and is not approved for human or veterinary use.